Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome Solution

The Foundation for Orthopaedics and Regenerative Medicine

Status and phase: Completed; Phase 1

Conditions: Motor Disorders

Treatments: Biological: AlloEx exosomes

Study type: Interventional

Funder types: Other

Identifiers

NCT07105371

FOREM2024EX01

Details and patient eligibility

About

Patients with ALS and other Motor Discorders will be treated with mesenchymal cell exosome solution.

Full description

Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.

Enrollment: 18 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients will need a diagnosis established by a neurologist. Patients must be able to provide informed consent, or have a guardian who does. They must be able to travel to the site of treatment.

Exclusion criteria

• Patients were excluded from the trial if they were pregnant or had active cancer at the screening consultation.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

18 participants in 1 patient group

Treatment Group (AlloEx)

Experimental group

Treatment:

Biological: AlloEx exosomes